NSEAction(s) initiated or orders passed29 Sept 2026 · 29 Sept 2026, 01:03 pm

Action(s) initiated or orders passed

Pfizer Limited · PFIZER

✦ AI SummaryRegulatory

Pfizer Limited has received a penalty of Rs. 1,26,34,050 from the Deputy / Additional Commissioner of Income tax Transfer Pricing for non-furnishing of specific granular information during a transfer pricing audit for the Assessment Year 2023-24.

Analysis Scores

Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment4/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer Pricing, levying a penalty of Rs. 1,26,34,050/- based on the Transfer Pricing audit conducted for the Assessment Year 2023-24.

Attachments (1)

📄

PFIZER_29092026130308_Stock_Exchange_Intimation_-_Regulation_30.pdf

pdf

Download →
View document text
Pfizer Limited The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274 September 29, 2026 The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1st Floor, P.J.Towers Exchange Plaza, 5th Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER Dear Sirs / Madam, Sub: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer Pricing, levying a penalty of Rs. 1,26,34,050/- based on the Transfer Pricing audit conducted for the Assessment Year 2023-24. Based on the Company’s assessment, the Company believes that the said Order is not maintainable. The Company is in the process of preferring an appeal against the said Order. The Order has no material impact on the financials, operations or other activities of the Company. The additional details required to be disclosed pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure – A. Request you to please take the above on record. Thanking you, Yours truly, For Pfizer Limited Prajeet Nair Director – Corporate Services & Company Secretary Encl.: A/a CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in Annexure A Additional information pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Sr. Particulars Details 1 Name of Authority Deputy / Additional Commissioner of Income tax Transfer Pricing. 2 Nature and details of the action(s) The Order received under Section 271G of the taken or order(s) passed Income tax Act, 1961 levying a penalty of Rs. 1,26,34,050/- (Rupees One Crore Twenty Six Lakh Thirty Four Thousand and Fifty only). 3 Date of receipt of direction or order September 28, 2026 4 Details of the violation(s) / The Deputy / Additional Commissioner of Income contravention(s) committed or tax Transfer Pricing has levied a penalty on the alleged to be committed Company due to alleged non-furnishing of specific granular information sought during the transfer pricing audit conducted for Assessment Year 2023-24. 5 Impact on financial, operation or Based on a preliminary assessment, the Company other activities of the listed entity, believes that it has strong grounds on merits. The quantifiable in monetary terms to Company does not expect the said order to have the extent possible any material impact on its financial position, operations or other activities.